
Entrada Therapeutics (TRDA) Stock Forecast & Price Target
Entrada Therapeutics (TRDA) Analyst Ratings
Bulls say
Entrada Therapeutics Inc. demonstrates a positive financial outlook driven by its broad pipeline of exon-skipping therapies for Duchenne muscular dystrophy (DMD), positioning the company as a comprehensive treatment provider in this area. In the first quarter of 2025, the company reported a net loss of $0.42 per share, which was significantly better than the anticipated loss of $0.92 per share, primarily due to higher-than-expected top-line revenue of $20.1 million. Additionally, the recent European Union authorization of the ELEVATE-44-201 program enhances the company’s clinical momentum, further bolstering investor confidence in its growth potential.
Bears say
Entrada Therapeutics Inc faces significant risks that contribute to a negative outlook for its stock, including the possibility of failing to generate positive mid-stage clinical data, which is critical for the advancement of its therapeutic candidates. Additionally, the company may struggle to timely progress its lead programs into pivotal trials, and any adverse outcomes from these pivotal studies could adversely impact investor confidence and stock performance. Furthermore, partnership-related uncertainties and the potential for long-term dilution due to financing needs present additional financial concerns that could hinder the company's growth prospects.
This aggregate rating is based on analysts' research of Entrada Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Entrada Therapeutics (TRDA) Analyst Forecast & Price Prediction
Start investing in Entrada Therapeutics (TRDA)
Order type
Buy in
Order amount
Est. shares
0 shares